TrialActa dermato-venereologica2026

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Andreas Wollenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.